Table 2 Clinical characteristics of participants with RA
Characteristic | RA (n = 24) |
|---|---|
RF positive, n (%) | 14 (63) |
Anti-CCP positive, n (%) | 14 (58) |
RF or anti-CCP positive, n (%) | 16 (67) |
Disease duration (years), median (IQR) | 7 (3, 13) |
DAS-28 CRP, median (IQR) n = 23 | 1.77 (1.23, 3.13) |
Prednisone use, n (%) | |
Current | 3 (13) |
Past | 19 (79) |
Never taken | 2 (8) |
Current prednisone dose (mg/day), median (IQR) | 5 (5, 5) |
Patients on any DMARD, n (%) | 24 (100) |
Current DMARD use, n (%)a | |
Methotrexate | 8 (33) |
Hydroxychloroquine | 7 (29) |
Sulfasalazine | 0 (0) |
Etanercept | 2 (8) |
Adalimumab | 6 (25) |
Infliximab | 1 (4) |
Abatacept | 0 (0) |
Rituximab | 1 (4) |
Tocilizumab | 2 (8) |
Tofacitinib | 3 (12) |